Présentation de l'entreprise
CVRx, Inc. operates as a commercial-stage medical device company dedicated to developing, manufacturing, and commercializing neuromodulation solutions specifically for patients suffering from cardiovascular diseases across the United States, Germany, and international markets. The firm focuses on the creation and deployment of implantable devices, such as the Barostim system, which delivers electrical stimulation to modulate physiological responses. This entity functions within the Healthcare sector, specifically targeting the Medical Devices industry, a segment characterized by rigorous regulatory requirements and high barriers to entry that distinguish it from general consumer goods or software sectors. The company's market capitalization stands at $206.02M, supported by an annual revenue of $56.65M and an organizational structure comprising 223 employees. These financial metrics indicate a mid-sized market position where the capitalization reflects a valuation that is substantial relative to its current revenue base, suggesting significant investor interest despite the lack of profitability, while the employee count implies a lean operational model typical of specialized biotechnology and device development firms.
Santé financière
The company reports a trailing twelve-month revenue of $56.65M, yet it simultaneously posts a net income loss of $-53,306,000 and an EBITDA of $-50,509,000. The substantial disparity between the $56.65M in revenue and the negative net income reveals a cost structure where operating expenses and research and development costs significantly exceed gross profits, resulting in a net loss that is nearly equal to total revenue. Free cash flow for the period is recorded at $-23,787,500, indicating that the company is currently burning cash, which limits its immediate financial flexibility and reliance on external capital sources to fund operations. Margins reflect this financial pressure: the Gross Margin is 85.3%, demonstrating strong pricing power or low cost of goods sold, while the Operating Margin sits at -69.8% and the Profit Margin at -94.1%, highlighting that overhead and R&D costs are eroding nearly all of the gross profit. The balance sheet shows a cash position of $75.71M against total debt of $50.50M, with a Debt to Equity ratio of 128.43, suggesting a leveraged capital structure where liabilities exceed equity, although the substantial cash reserve provides a buffer against short-term solvency concerns. Liquidity is robust as evidenced by a Current Ratio of 7.63, which indicates the company holds more than seven times the current assets required to cover its current liabilities, minimizing immediate liquidity risk. Return metrics further illustrate the current stage of development: Return on Equity is -96.6% and Return on Assets is -26.9%, revealing that management has not yet generated returns on the capital invested, a common characteristic of pre-profitability growth-stage biotech and device companies.
Évaluation de la valorisation
Valuation multiples present a complex picture given the lack of earnings: the Trailing P/E Ratio is listed as N/A, while the Forward P/E is -4.41, implying that the market is pricing in expected future earnings recovery or continuing losses, making traditional trailing earnings-based valuation impossible. The Price to Book ratio stands at 5.24, indicating that the market values the company's equity at more than five times its book value, which suggests investors are paying a significant premium for the company's intangible assets, proprietary technology, and growth potential rather than current asset value. Alternative valuation metrics such as the Price to Sales ratio of 3.64 and an EV/EBITDA of -3.58 provide insight into the relative cost of acquiring the business, suggesting the market is willing to pay a multiple of roughly 3.6 times sales despite the negative earnings power. Price action over the last year ranges between a low of $4.30 and a high of $11.30, placing the stock's current trajectory within a volatile range that reflects high uncertainty regarding future commercialization milestones. The Beta of 1.12 indicates that the stock's price volatility is approximately 12% higher than the broader market, meaning the asset will likely experience amplified swings in response to general market movements or sector-specific news.
Growth & Income
Revenue growth over the last year is 4.4%, whereas Earnings Growth is N/A due to the absence of positive earnings in the trailing period. Since there are no earnings to compare, the 4.4% revenue expansion represents the primary driver of company expansion, though the lack of earnings growth data precludes a direct comparison of profitability acceleration. The company does not distribute dividends, as evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, confirming that all retained earnings are being reinvested into research, development, and commercialization efforts rather than distributed to shareholders. Consequently, the overall growth and income profile is defined exclusively by top-line revenue expansion and capital efficiency, with income generation remaining a future objective dependent on successful product adoption and regulatory approvals in target markets.